Patriot Financial Group Insurance Agency LLC Acquires Shares of 16,800 uniQure N.V. $QURE

Patriot Financial Group Insurance Agency LLC acquired a new stake in uniQure N.V. (NASDAQ:QURE) during the first quarter, Holdings Channel.com reports. The firm acquired 16,800 shares of the biotechnology company’s stock, valued at approximately $275,000.

Several other institutional investors have also modified their holdings of QURE. Vanguard Group Inc. increased its holdings in uniQure by 15.7% in the third quarter. Vanguard Group Inc. now owns 1,125,108 shares of the biotechnology company’s stock valued at $65,673,000 after buying an additional 152,417 shares during the last quarter. Aberdeen Group plc lifted its holdings in uniQure by 25.1% during the 4th quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock worth $88,030,000 after buying an additional 738,897 shares during the last quarter. Quinn Opportunity Partners LLC purchased a new stake in uniQure during the 3rd quarter worth about $6,281,000. Farallon Capital Management LLC boosted its position in shares of uniQure by 3,935.7% during the 3rd quarter. Farallon Capital Management LLC now owns 565,000 shares of the biotechnology company’s stock worth $32,979,000 after acquiring an additional 551,000 shares in the last quarter. Finally, Boone Capital Management LLC acquired a new position in shares of uniQure during the 3rd quarter worth about $8,599,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and $80 price target while raising multiple earnings estimates for uniQure, including near- and longer-term forecasts. The improved outlook suggests analysts see stronger future profitability than before. uniQure analyst update
• Positive Sentiment: Recent technical coverage highlighted that QURE is trading above a golden cross, which traders often view as a bullish momentum signal and a possible support level. Zacks golden cross article
• Neutral Sentiment: Media attention also included a comparison piece on uniQure versus Viridian Therapeutics and a short-squeeze watchlist mention, which may be adding trading interest but does not directly change fundamentals. AAII comparison article
• Negative Sentiment: Director Jack Kaye and insider Walid Abi-Saab both sold shares in recent SEC filings. Although the trades were made under pre-arranged 10b5-1 plans, insider selling can still weigh on sentiment. Jack Kaye SEC filing Walid Abi-Saab SEC filing

Wall Street Analysts Forecast Growth

QURE has been the topic of several research analyst reports. Chardan Capital raised their target price on uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. HC Wainwright upped their price target on uniQure from $50.00 to $80.00 and gave the company a “buy” rating in a report on Monday. Royal Bank Of Canada increased their price target on shares of uniQure from $35.00 to $65.00 and gave the company an “outperform” rating in a research note on Thursday, June 18th. Leerink Partners raised their price objective on shares of uniQure from $36.00 to $70.00 and gave the stock an “outperform” rating in a report on Thursday, June 18th. Finally, The Goldman Sachs Group boosted their price objective on shares of uniQure from $14.00 to $46.00 and gave the stock a “neutral” rating in a research report on Thursday, June 18th. Twelve investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $64.17.

uniQure Trading Down 7.4%

Shares of uniQure stock opened at $41.81 on Friday. uniQure N.V. has a 1 year low of $8.73 and a 1 year high of $71.50. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.40 and a current ratio of 10.40. The company has a market capitalization of $2.64 billion, a P/E ratio of -12.01 and a beta of 0.90. The company’s fifty day moving average is $30.05 and its two-hundred day moving average is $23.73.

uniQure (NASDAQ:QURE) last announced its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The business had revenue of $3.56 million during the quarter, compared to analysts’ expectations of $5.21 million. Analysts forecast that uniQure N.V. will post -3.63 earnings per share for the current year.

Insider Transactions at uniQure

In related news, insider Kylie O’keefe sold 15,936 shares of the business’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $27.06, for a total value of $431,228.16. Following the transaction, the insider owned 108,864 shares in the company, valued at $2,945,859.84. The trade was a 12.77% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Matthew C. Kapusta sold 164,429 shares of the company’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $44.32, for a total value of $7,287,493.28. Following the sale, the chief executive officer directly owned 558,810 shares of the company’s stock, valued at approximately $24,766,459.20. This represents a 22.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 412,147 shares of company stock worth $16,992,736 over the last three months. 4.65% of the stock is currently owned by company insiders.

uniQure Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.